Full index of posts »
StockTalks
-
BioRunUp subs, webinar today @ 4:30pm EST. If you are not a subscriber, join for todays webinar w/ a FREE 14 day trial http://biot.ec/join
Dec 1, 2011
-
Embarrassing Photo Of One Of My Vegas Conference Speakers [YOWZA!] http://bit.ly/qbmcit
Sep 25, 2011
-
@BioRunUp @mikehavrilla mention => Profit.ly mines the masses for stock-trading gold - Forbes http://onforb.es/pwXkq0
Sep 15, 2011
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.












View Mike Havrilla's Instablogs on:
BioRunUp's Pick of AMRN up 130% / Now Offering New $49 Monthly Plan
BioRunUp Mobile App Launches on iTunes, New Features Planned for Website
The mobile app is free to download and a subscription of $10 a month is required for access to the information and was developed in partnership with CERMUSA, which is the reason for a separate subscription plan to complement the existing website service.
In addition, BioRunUp.com will adopt new pricing plans on December 15, 2010, that include $49.95 per month and $495 per year options along with a new feature for a members-only Twitter account to post Mark and Mike's stock trades - allowing subscribers to receive SMS text / email alerts, or internet updates for stock trades with more details posted on the forum. Please visit the link below for the BioRunUp.com Users Guide...
http://www.biorunup.com/categories/User_Guide
The database is sorted by catalyst date with soonest events listed first by default and users can search the database by company name, ticker, product, etc. for quick access to the information. Also, the entries can be sorted by last updated for those seeking quick access to the latest updates in the database. Below are the specs for the BioRunUp mobile app at iTunes, with Android launch to follow shortly then Blackberry...
http://itunes.apple.com/us/app/biorunup/id403993126?mt=8
Free to download, $10/month to subscribe
Category: Finance
Released: Nov 19, 2010
Version: 1.0
1.0 (iOS 4.0 Tested)
3.1 MB
Language: English
Seller: Saint Francis University's Center of Excellence for Remote & Medically Under-Served Areas (CERMUSA)
Requirements: Compatible with iPhone, iPod touch, and iPad. Requires iOS 3.1 or later
© 2010 BioRunUp, LLC
Rated 4+
BioRunUp / mikehavRx Merger: More Resources to Profit from FDA, Clinical Trial Binary Events
BioRunUp.com is the best resource on the Internet for making consistent gains trading bio-pharmaceutical stocks. For those not familiar with the Run-Up method, here is the concept...Companies spend between $325-750 million from development to approval of a new drug as part of a process that takes about 8-10 years. This begins with the creation of the drug, followed by Phase I, II, and III clinical trials - all under the watchful eye of the FDA. Only at this point are some drugs assigned a date, at which approval or denial is to be announced. This decision date (PDUFA) is known at least 6 months in advance.
The Run-Up method involves locating and buying shares of these companies well before their decision date, riding the share price up, and selling BEFORE the FDA announces their decision. The concept can also be applied to clinical trials with data releases, but the goal is the same - minimize risk while maximizing profits and achieving this on a consistent basis.
However, not every FDA / Clinical catalyst event will result in a run-up. When taking into account what stocks to discuss we take into account many factors, including (but not limited to) the following: market cap, potential market for drug / device / diagnostic in development, cash resources / potential for dilution or financing, market / analyst perception of FDA approval / trial success, partnership status, management reputation / track record, insider buying / selling, percentage institutional / fund ownership.
Research, Research, and more Research...By the time you hear about one of these stocks in the news it is too late. The best profits are made by getting in before the masses. This is what BioRunUp.com subscription service provides for you. We are constantly researching and using every resource available to find the next catalyst event. The FAQS page provides an overview of common abbreviations and terms associated with the drug development process, including clinical trials, the FDA approval process, and useful Web links / resources for additional information.
Currently, the following categories are offered to subscribers at BioRunUp.com: Articles, Analyst Reports, BioRunUp's Trading Account, Catalyst Roadmap, Email Alerts Email, FDA Events Google Calendar Tracking, Members Only Forum, SMS Text Alerts, Valuation Studies, Weekly Newsletter, HavRx Healthcare Stock Indexes, mikehavRx Portfolio and Stock Watch List, Corporate Event Google Calendar Tracking for Bio-Catalyst Stocks, and the Clinical / Regulatory Bio-Catalyst Spreadsheet Tracking Database (which also includes an embedded table that is integrated with Google Docs / Finance).
Corporate Event Calendar for Bio-Catalyst Stocks...tracks presentations, quarterly earnings announcements, and other corporate events for all stocks included in the clinical / regulatory catalyst calendar database.
Clinical and Regulatory Bio-Catalyst Spreadsheet, Google Docs / Finance Tracking Database...tracks pending FDA / clinical trial binary events such as FDA decisions, FDA Advisory Panel meetings, clinical trial results / presentations, and pending FDA filings / clinical trials.
Mike Havrilla's (Profit.ly trading stats) Portfolio Tracker / Watch List, Trading Account for BioRunUp (Profit.ly trading stats)...The Bio-Catalyst, Rotating Run-Up Strategy is an active, flexible trading strategy with a targeted basket of 3-7 stocks with pending FDA or clinical trial catalyst events that seeks to rotate / position trade (i.e. sell gainers and buy or add to a position for catalyst stocks of interest with stock prices that are down or flat) based on market conditions and stock prices. The information flow includes the clinical / regulatory catalyst calendar database as the primary research source, which is refined to a top 10 stock watch list and 3-7 stock portfolio that is updated based on new developments and stock prices.
Subscribers receive premium access to BioRunUp's trading account / screen capture image and Mike's portfolio tracker auto-update widget - which also includes an updated top 10 stock watch list, screen capture image of his TD Ameritrade account, link to Profit.ly trading stats, and link to Mike's members-only forum thread that includes his stock trades / strategy. The members-only forum also provides threads for active FDA catalyst stocks, clinical trial event stocks, completed catalysts, and other topics.
The basket of 3-7 stocks is chosen approx. 2-3 months ahead of an FDA event (decision or advisory panel event) or clinical trial catalyst (preferably late-stage or pivotal studies) with a goal of achieving stock price gains and profits by selling ahead of the catalyst event. The exact timing of stock buys ahead of the catalyst date is not as important as screening for stocks that are preferably trading near or below the mid-point of their 52-week price range and at low or average trading volumes, which indicates that the stock is largely unnoticed by traders with the potential to experience increases in both share price and trading volume as the catalyst date nears.
Bio-Catalyst Roadmap...Seeks to identify stocks on a timely basis for potential run-up trades...for example, September Buys: Avanir Pharma (NASDAQ:AVNR) (10/30 PDUFA Date), Biodel (NASDAQ:BIOD) (10/30 PDUFA Date), Jazz Pharma (NASDAQ:JAZZ) (10/11 PDUFA Date), and EXACT Sciences (NASDAQ:EXAS) (10/29 Data Release). September Sells: Arena Pharma (NASDAQ:ARNA) (Pre FDA Advisory Panel Notes), Alkermes (NASDAQ:ALKS) (Pre FDA Advisory Panel Notes).
Detailed Valuation Studies and Bio-Analysis Reports...These valuation studies include extremely detailed information on FDA catalyst run-ups. Using industry valuation models, we attempt to calculate the true run-up potential of a binary catalyst.
Weekly Newsletter / Watch List, e.g. 10/11/10...this week unofficially starts the long anticipated 'Super Bowl' of biotech catalysts. This week alone we have FOUR FDA decisions...
HavRx Healthcare Stock Indexes: 10 passively managed, sub-sector healthcare indexes tracked by Google Docs / Finance, including stem cells / regenerative medicine, generic drugs, Health IT, health benefit providers, hospitals / facilities, emerging cancer diagnostic / therapeutic (Dx / Tx), immune therapy / vaccines, cosmetic / restorative medicine, diabetes care, and crop science.
These indexes can be used to identify potential plays within a sub-sector of healthcare stocks to identify potential acquisition targets in the rapidly consolidating generic drug or Health IT industries, undervalued stem cell / regenerative medicine companies, the next Dendreon (NASDAQ:DNDN) from the immune therapy / vaccines index, etc.
Please use merger promo code “mikehavrx” for a $245 one-year, non-recurring subscription ($50 discount) rate.